Can 'Peacekeeper' cells stop diabetes in its tracks?
NCT ID NCT05207995
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested whether a new type of immune cell, called a tolerogenic dendritic cell, is safe for people with type 1 diabetes. The cells were made from each patient's own blood and designed to calm the immune system attack on the pancreas. 32 participants received the cells or standard care, and researchers monitored blood sugar, insulin markers, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tolerogenic dendritic cells (immune cells trained to calm the immune system)
What this could lead to
If successful, this approach could point toward a way to preserve insulin production in type 1 diabetes without lifelong immune suppression.
What could go wrong
This is an early-phase safety study with only 32 participants. It is not designed to prove effectiveness, and the treatment may not work or may have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Healthcare institution "Minsk City Clinical Endocrinology Center"
Minsk, 220000, Belarus